GSK reports 2,501.842-share transaction on Aug 21, 2025

GSK plc filed a Form 6-K reporting a transaction notification dated August 21, 2025.

Accepted by SEC EDGAR 08/21/2025 - 11:13 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

GSK plc filed a Form 6-K reporting a transaction notification dated August 21, 2025. The notice identifies the security by ISIN US37733W2044 and discloses an aggregated traded volume of 2,501.842 (shares/units as stated). The filing indicates the company files annual reports on Form 20-F. The document does not provide a transaction price, counterparty, or the exact nature of the trade beyond the aggregated volume and ISIN, so further detail about value or economic impact is not available from the text provided.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did GSK (GSK) report on Aug 21, 2025?

The filing reports a transaction tied to ISIN US37733W2044 with an aggregated volume of 2,501.842 on August 21, 2025.

Does the Form 6-K state the trade price for the GSK transaction?

No. The document does not disclose a price for the reported transaction.

What form does GSK use for annual reports according to the filing?

The filing indicates GSK files annual reports under Form 20-F.

Is the counterparty or nature of the transaction specified?

No. The filing does not specify the counterparty or detailed nature of the transaction beyond the aggregated volume and ISIN.

Where can I find more details about this transaction?

More details would typically appear in expanded SEC filings or company disclosures; this Form 6-K only provides ISIN and aggregated volume for the August 21, 2025 entry.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Shobie Ramakrishnan
b)	Position/status	Chief Digital and Technology Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	Following the vesting on 19 August 2025 of 25% of an award made on 19 August 2019 under the GlaxoSmithKline Deferred Investment Award Programme, Ms Ramakrishnan will receive a cash payment of $99,122.98 less applicable tax withholding in respect of 2,501.842 notional ADSs.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$39.6200	2,501.842
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2025-08-19
f)	Place of the transaction	N/A

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: August 21, 2025

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc